| 신라젠

컨텐츠 바로가기

Targeting, Attacking, and Eradicating Cancers®

Scientific Publications

10 cases in total ˙ 1/1 Page

Clinical
Preclinical
Review
Poster

Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans

Mol Ther. 2013 Feb.

NO 10
Phase I Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients with Advanced Solid Cancers.

Mol Ther. 2016 May.

NO 9
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.

Mol Ther. 2015 Sep.

NO 8
A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.

Methods Mol Biol. 2015

NO 7
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.

Mol Ther. 2015 Mar.

NO 6
First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.

Mol Ther. 2015 Jan.

NO 5
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Nat Med. 2013 Mar.

NO 4
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Nature. 2011 Aug.

NO 3
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Lancet Oncol. 2008 Jun.

NO 2
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.

Cancer Gene Ther. 1999 Sep.

NO 1